Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma

Toni K. Choueiri, Piotr Tomczak, Se Hoon Park, Balaji Venugopal, Tom Ferguson, Stefan N. Symeonides, Jaroslav Hajek, Yen-Hwa Chang, Jae-Lyun Lee, Naveed Sarwar, Naomi B. Haas, Howard Gurney, Piotr Sawrycki, Mauricio Mahave, Marine Gross-Goupil, Tian Zhang, John M. Burke, Gurjyot Doshi, Bohuslav Melichar, Evgeniy Kopyltsov, Ajjai Alva, Stephane Oudard, Delphine Topart, Hans Hammers, Hiroshi Kitamura, David F. McDermott, Adriano Silva, Eric Winquist, Jerry Cornell, Aymen Elfiky, Joseph E. Burgents, Rodolfo F. Perini, Thomas Powles

Open source

DOI: 10.1056/nejmoa2312695
Published: 2024-04-18
Container: New England Journal of Medicine
Publisher: Massachusetts Medical Society
Open access: unknown

Credibility signals

uncertain Score 64/100 under policy 1.0.0. This is a metadata assessment, not a judgment of the paper's conclusions.

Show all credibility signals

supportingDOI registered: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
supportingDOI resolves: A matching record was returned by Crossref. Source: Crossref; license: CC0 metadata
not scoredDirectory of Open Access Journals: No matching DOAJ record was present in this response. No allow-list match; this is not evidence of low credibility. Source: DOAJ; license: CC0
not scoredMEDLINE indexed: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredOpenAlex core source: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredKnown publisher allow-list: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredROR affiliation: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredRetraction Watch retraction: No retraction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch expression of concern: No expression of concern notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch correction: No correction notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredRetraction Watch reinstatement: No reinstatement notice matched this DOI in the deployed snapshot. No matching event found; coverage may be incomplete. Source: Retraction Watch; license: CC BY 4.0
not scoredOpen access status: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication license: Not checked or no result supplied; no credibility inference made. Source: No authority result supplied; license: Unknown
not scoredPublication version: A publication version was supplied but is not scored. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer
supportingMetadata completeness: All 6 scored descriptive metadata groups are present. Source: Normalized work metadata; license: Caller-provided; provenance license not supplied to scorer

Cite this work

BibTeX

@article{allodium:10.1056/nejmoa2312695,
  title = {Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma},
  author = {Toni K. Choueiri and Piotr Tomczak and Se Hoon Park and Balaji Venugopal and Tom Ferguson and Stefan N. Symeonides and Jaroslav Hajek and Yen-Hwa Chang and Jae-Lyun Lee and Naveed Sarwar and Naomi B. Haas and Howard Gurney and Piotr Sawrycki and Mauricio Mahave and Marine Gross-Goupil and Tian Zhang and John M. Burke and Gurjyot Doshi and Bohuslav Melichar and Evgeniy Kopyltsov and Ajjai Alva and Stephane Oudard and Delphine Topart and Hans Hammers and Hiroshi Kitamura and David F. McDermott and Adriano Silva and Eric Winquist and Jerry Cornell and Aymen Elfiky and Joseph E. Burgents and Rodolfo F. Perini and Thomas Powles},
  year = {2024},
  journal = {New England Journal of Medicine},
  doi = {10.1056/nejmoa2312695},
  url = {https://doi.org/10.1056/nejmoa2312695}
}

RIS

TY  - JOUR
TI  - Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma
AU  - Toni K. Choueiri
AU  - Piotr Tomczak
AU  - Se Hoon Park
AU  - Balaji Venugopal
AU  - Tom Ferguson
AU  - Stefan N. Symeonides
AU  - Jaroslav Hajek
AU  - Yen-Hwa Chang
AU  - Jae-Lyun Lee
AU  - Naveed Sarwar
AU  - Naomi B. Haas
AU  - Howard Gurney
AU  - Piotr Sawrycki
AU  - Mauricio Mahave
AU  - Marine Gross-Goupil
AU  - Tian Zhang
AU  - John M. Burke
AU  - Gurjyot Doshi
AU  - Bohuslav Melichar
AU  - Evgeniy Kopyltsov
AU  - Ajjai Alva
AU  - Stephane Oudard
AU  - Delphine Topart
AU  - Hans Hammers
AU  - Hiroshi Kitamura
AU  - David F. McDermott
AU  - Adriano Silva
AU  - Eric Winquist
AU  - Jerry Cornell
AU  - Aymen Elfiky
AU  - Joseph E. Burgents
AU  - Rodolfo F. Perini
AU  - Thomas Powles
PY  - 2024
JO  - New England Journal of Medicine
DO  - 10.1056/nejmoa2312695
UR  - https://doi.org/10.1056/nejmoa2312695
ER  -

APA

Choueiri, T. K., Tomczak, P., Park, S. H., Venugopal, B., Ferguson, T., Symeonides, S. N., Hajek, J., Chang, Y., Lee, J., Sarwar, N., Haas, N. B., Gurney, H., Sawrycki, P., Mahave, M., Gross-Goupil, M., Zhang, T., Burke, J. M., Doshi, G., Melichar, B., Kopyltsov, E., Alva, A., Oudard, S., Topart, D., Hammers, H., Kitamura, H., McDermott, D. F., Silva, A., Winquist, E., Cornell, J., Elfiky, A., Burgents, J. E., Perini, R. F., & Powles, T. (2024). Overall Survival with Adjuvant Pembrolizumab in Renal-Cell Carcinoma. New England Journal of Medicine. https://doi.org/10.1056/nejmoa2312695

Source records

crossref · retrieved 2026-09-26T11:19:30.024Z